{"name":"Shanghai Auzone Biological Technology Co., Ltd.","slug":"shanghai-auzone-biological-technology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Radicava ORS","genericName":"Radicava ORS","slug":"radicava-ors","indication":"Amyotrophic lateral sclerosis (ALS)","status":"marketed"},{"name":"Radicava","genericName":"Radicava","slug":"radicava","indication":"Amyotrophic lateral sclerosis","status":"marketed"},{"name":"TTYP01, 120 mg","genericName":"TTYP01, 120 mg","slug":"ttyp01-120-mg","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"TTYP01 tablets","genericName":"TTYP01 tablets","slug":"ttyp01-tablets","indication":"Treatment of COVID-19","status":"phase_3"}]}],"pipeline":[{"name":"Radicava ORS","genericName":"Radicava ORS","slug":"radicava-ors","phase":"marketed","mechanism":"Radicava ORS is an oral formulation of edaravone that acts as a free radical scavenger to reduce oxidative stress in motor neurons.","indications":["Amyotrophic lateral sclerosis (ALS)"],"catalyst":""},{"name":"Radicava","genericName":"Radicava","slug":"radicava","phase":"marketed","mechanism":"Polyunsaturated fatty acid lipoxygenase ALOX15","indications":["Amyotrophic lateral sclerosis","Ischemic stroke"],"catalyst":""},{"name":"TTYP01 tablets","genericName":"TTYP01 tablets","slug":"ttyp01-tablets","phase":"phase_3","mechanism":"TTYP01 tablets are a small molecule drug that targets the SARS-CoV-2 main protease.","indications":["Treatment of COVID-19"],"catalyst":""},{"name":"TTYP01, 120 mg","genericName":"TTYP01, 120 mg","slug":"ttyp01-120-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxQTWpOenEwRS1rZGJ5T2J4YWQzNllmQlBtVVBzMHVuNE1HbGo4VVU0VF94SGQ4RlZlUk9jRGRMR3RkMjNYQnZ2U3JKdFB4d0dRNXRHUHU1SFJ2RUd1ZTZWLWlWN1NEOGpQNlhUTlV4ejc4MzVpVTI1ODBVRHpKcEFiV3EycWFXMXVSd3F4aHpFWkNDUmExWjNZMWx2Z05USG1kVW9ZNUZZSHE2aE9Wc2QzZk1lbGFJMmJuaTNkWC03UEhWVnFTdUdFNDZ5QW5BeFRVVkEySlJMWndGMUhSR3duTDlvb29ERTIyYWtxeUFrR0xyZ3RHLVJXN3F1ZGZwSl80MmlGNmwyVTlGalN4S0VVXzRBVTZ6dGtfcXRpZG1ER2s0MGd3eDVVTEdlcEJRWHJC?oc=5","date":"2026-03-12","type":"regulatory","source":"Akin","summary":"Try, Try Again: District Court Orders Quarreling Parties to Reach Agreement Concerning Scope of FDA and Patent Prosecution Bar Without Court Intervention - Akin","headline":"Try, Try Again: District Court Orders Quarreling Parties to Reach Agreement Concerning Scope of FDA and Patent Prosecuti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxOZFFXbjY5X19SVW9xSlRDdjdlUkgzYnRNbnFFRzU5WjBwUXpyS2xYRm5Sd2sxWndTZ3RpOHFiNEJjbU1CXzg1M3hwSkN5TW1tY05TZG5BMmtGNmZNS1F5WGRxR3F5MzhqSnRzWndvaS0zMGgxQWdfU2VwU1V2ckZxYVVEOGxDRlMzTEVsZm5yU045QWhLWURlTXdRcFhXSXZTb0h0WjVBMklWTTNLVG5hdm04MG1hWUJXUEdUSFlnZHNPT2VuNlFkNXEtVGNXc1FPang4Q09JOVVKMjNTYjB2ZHd3QlVlUC13ZkR2RG5OV0llZ3hicUg5SjdPc1lieXE4eUR0X2lnRTY0SUlDTzRPV1dpQU1tMWRDYjZGTGh1enZpS1RJa2w1SWRtbWF4dw?oc=5","date":"2025-06-26","type":"trial","source":"GlobeNewswire","summary":"Autism Spectrum Disorder Clinical Trial Analysis: Key - GlobeNewswire","headline":"Autism Spectrum Disorder Clinical Trial Analysis: Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQb0x1TXlaUGk2UlVDQ1ZxdHFwU1hVeG5hLTB5TUVPMDV6RElFLU1wRnppR3hHek5KSGg0NVFGVXJIbXU5US1wUWhoUFhVUng1U0VuLXJ0cnBKTzR3VjhleVUwSVpGWnBQLW1kS0hSUnljLWFZYWJwVjgzMjVUd1d5aDZiakxJRW9SYkE5ZUxRN2dDNWtkX0pRc3h5WU5jYkJNQ2VrWXdwWjdSZU4zY3R3enB5bnM2dkpSWWtRZg?oc=5","date":"2024-07-15","type":"deal","source":"Yicai Global","summary":"Huadong Buys China Rights to Auzone’s Pioneering Stroke Tablets for Up to USD179 Million - Yicai Global","headline":"Huadong Buys China Rights to Auzone’s Pioneering Stroke Tablets for Up to USD179 Million","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":2,"phase_3":1,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}